Stocktoria
HCW Biologics Inc. HCWB
HCW Biologics Inc. financials (annual)
Bars are annual figures from 2020 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $54,232 | $2.6M | $2.8M | $6.7M | $0 | $4.1M |
| Gross profit | $10,846 | $959,403 | $560,360 | $2.6M | $0 | — |
| R&D expense | $5.4M | $6.4M | $7.7M | $9.3M | $8.2M | $7.3M |
| Operating income | -$13.2M | -$29.5M | -$25.7M | -$15.1M | -$13.4M | -$5.8M |
| Interest expense | $845,051 | $654,284 | $283,042 | $126,660 | $0 | — |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$8.0M | -$30.0M | -$25.0M | -$14.9M | -$12.9M | -$5.8M |
| EPS (diluted) | $-10.63 | $-30.96 | $-0.70 | $-0.42 | $-0.69 | — |
| Operating cash flow | -$13.4M | -$14.2M | -$22.5M | -$10.4M | -$11.0M | -$10.4M |
| Free cash flow | -$13.4M | -$14.5M | -$28.7M | -$20.7M | -$11.0M | -$10.6M |
| Cash & equivalents | $2.0M | $4.7M | $3.6M | $22.3M | $11.7M | $8.5M |
| Total assets | $24.5M | $30.2M | $28.5M | $46.8M | $53.5M | $15.4M |
| Total liabilities | $21.8M | $37.0M | $15.1M | $9.4M | $2.3M | — |
| Shareholders' equity | $2.8M | -$6.8M | $13.5M | $37.4M | $51.2M | -$16.7M |
Growth · year-over-year · Revenue CAGR -57.9%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue growth | -97.9% | -9.7% | -57.7% | — | -100.0% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.